As inhibition of DPP-4 prolongs the life of incretins (GLP-1 and GIP), which in turn induce insulin secretion, many DPP-4 inhibitors like sitagliptin and vildagliptin are emerging as powerful adjuncts in the treatment of type 2 diabetes [31]. This evidence concerns the gene INS and type 2 diabetes mellitus.